摘要
目的观察对重症加强护理病房(ICU)重症肺炎患者行血必净联合抗菌药物治疗的临床效果。方法86例ICU重症肺炎患者,随机分为对照组和试验组,每组43例。对照组患者采用抗菌药物治疗,试验组患者采用血必净联合抗菌药物治疗。比较两组患者临床疗效、相关治疗时间及治疗前后临床指标。结果试验组患者治疗总有效率为93.02%,高于对照组的72.09%,差异具有统计学意义(P<0.05)。试验组患者退热时间、抗菌药物应用时间、机械通气时间、住院时间分别为(1.23±0.15)、(11.63±1.05)、(4.65±0.80)、(11.95±1.10)d,明显短于对照组的(2.60±0.46)、(18.25±1.50)、(10.17±1.26)、(19.95±1.70)d,差异具有统计学意义(P<0.05)。治疗后,试验组患者氧分压(PO_(2))(83.55±7.62)mm Hg(1 mm Hg=0.133 kPa)高于对照组的(70.83±8.36)mm Hg,二氧化碳分压(PCO_(2))(43.06±6.90)mm Hg、白细胞计数(WBC)(10.32±3.46)×10^(9)/L、临床肺部感染量表(CPIS)评分(1.91±0.38)分低于对照组的(54.55±7.06)mm Hg、(13.37±4.25)×10^(9)/L、(3.99±0.70)分,差异具有统计学意义(P<0.05)。结论对ICU重症肺炎患者行血必净联合抗菌药物治疗效果突出,建议临床推广应用。
Objective To observe the clinical effect of Xuebijing combined with antibiotics in intensive care unit(ICU)patients with severe pneumonia.Methods A total of 86 ICU patients with severe pneumonia were randomly divided into control group and experimental group,with 43 cases in each group.The control group was treated with antibacterial drugs,and the experimental group was treated with Xuebijing and antibacterial drugs.The clinical efficacy,treatment related time and clinical indexes before and after treatment were compared between the two groups.Results The total effective rate of the experimental group was 93.02%,which was higher than that of 72.09% of the control group,and the difference was statistically significant(P<0.05).The antipyretic time,antibiotic application time,mechanical ventilation time and hospitalization time of the experimental group were(1.23±0.15),(11.63±1.05),(4.65±0.80)and(11.95±1.10)d,which were significantly shorter than those of(2.60±0.46),(18.25±1.50),(10.17±1.26)and(19.95±1.70)d of the control group,and the differences were statistically significant(P<0.05).After treatment,the partial pressure of oxygen(PO_(2))of(83.55±7.62)mm Hg(1 mm Hg=0.133 kPa)in the experimental group was higher than that of(70.83±8.36)mm Hg in the control group;in the experimental group,the partial pressure of carbon dioxide(PCO_(2))was(43.06±6.90)mm Hg,the white blood cell count(WBC)was(10.32±3.46)×10^(9)/L,and the Clinical Pulmonary Infection Scale(CPIS)score was(1.91±0.38)points,which were lower than those of(54.55±7.06)mm Hg,(13.37±4.25)×10^(9)/L,and(3.99±0.70)points in the control group;the differences were statistically significant(P<0.05).Conclusion The combination of Xuebijing and antibacterial drugs is effective for ICU patients with severe pneumonia,and it is recommended to promote its clinical application.
作者
饶旭辉
RAO Xu-hui(Guangfeng District People's Hospital of Shangrao City,Shangrao 334600,China)
出处
《中国现代药物应用》
2023年第18期113-115,共3页
Chinese Journal of Modern Drug Application
